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Abstract The occurrence of metastases is a critical
determinant of the prognosis for breast cancer patients.
Effective treatment of breast cancer metastases is ham-
pered by a poor understanding of the mechanisms involved
in the formation of these secondary tumor deposits. To
study the processes of metastasis, valid in vivo tumor
metastasis models are required. Here, we show that
increased expression of the EGF receptor in the MTLn3 rat
mammary tumor cell-line is essential for efﬁcient lung
metastasis formation in the Rag mouse model. EGFR
expression resulted in delayed orthotopic tumor growth but
at the same time strongly enhanced intravasation and lung
metastasis. Previously, we demonstrated the critical role of
NK cells in a lung metastasis model using MTLn3 cells in
syngenic F344 rats. However, this model is incompatible
with human EGFR. Using the highly metastatic EGFR-
overexpressing MTLn3 cell-line, we report that only
Rag2
-/-cc
-/- mice, which lack NK cells, allow efﬁcient
lung metastasis from primary tumors in the mammary
gland. In contrast, in nude and SCID mice, the remaining
innate immune cells reduce MTLn3 lung metastasis for-
mation. Furthermore, we conﬁrm this ﬁnding with the
orthotopic transplantation of the 4T1 mouse mammary
tumor cell-line. Thus, we have established an improved in
vivo model using a Rag2
-/- cc
-/- mouse strain together
with MTLn3 cells that have increased levels of the EGF
receptor, which enables us to study EGFR-dependent
tumor cell autonomous mechanisms underlying lung
metastasis formation. This improved model can be used for
drug target validation and development of new therapeutic
strategies against breast cancer metastasis formation.
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Abbreviations
SCID Mice severe combined immunodeﬁciency mice
RAG2 Recombinase activating gene
cc Common gamma chain
FACS Fluorescence activated cell sorter
ErbB1 Epidermal growth factor receptor
GFP Plasmid green ﬂuorescent protein
IL-2 Interleukin 2
MHC Major histocompatibility complex
NK Cell natural killer cell
FLI Fluorescent imaging
APC Allophycocyanin
Introduction
Breast cancer is the most common cause of cancer among
women and the second leading cause of cancer deaths in
Western countries. The metastatic spread of tumor cells
from their primary site to distant organs in the body is the
principal cause of mortality [1]. Thus, understanding
metastasis is one of the most signiﬁcant problems in cancer
research [2–4]. A key challenge is to develop suitable
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mechanisms that underlie metastatic progression and to
evaluate treatments for metastatic diseases [5].
Currently available in vivo models of breast tumor
progression and metastasis include transplantable models
and genetically engineered mice that develop primary and
metastatic cancers [5–8]. Transplantable tumor models
include syngeneic models, in which the cancer cell line/
transplanted tissue is of the same genetic background as the
animal, and xenograft models whereby human cancer cell
lines or tissues are transplanted into immunocompromised
hosts, such as nude and severe combined immunodeﬁcient
mice [5]. Breast xenograft tumors are produced by inject-
ing breast cancer cells into the ﬂank (subcutaneous) or
preferably into the mammary fat pad (orthotopic) of a
female animal. Subcutaneous xenograft mouse models are
typically the standard for cancer drug screening in the
pharmaceutical industry [9], but the use of orthotopic xe-
notransplantation models should be favored since tissue
speciﬁc stromal cell interactions play a crucial role in the
biology of cancer progression and metastasis.
Metastasis is a consequence of multiple steps, including
growth of a primary tumor, intravasation, arrest and growth
in a secondary site [2, 3]. The study of metastasis requires
both a relevant mouse model and an appropriate tumor cell
line. On the basis of gene proﬁling and previous in vivo
results, rat mammary adenocarcinoma MTLn3 cells have
been identiﬁed as a suitable model to study breast cancer
progression and treatment [10, 11]. The epidermal growth
factor receptor (EGFR, also referred as ErbB1) is often
overexpressed in breast cancer, resulting not only in
uncontrolled cell proliferation [12, 13] but also in increased
tumor cell motility and invasion [14–16]. To study in-
travasation leading to metastasis formation, we therefore
evaluated the effect of enhanced ErbB1 signaling in
MTLn3 cells in the orthotopic Rag mouse breast cancer
model.
Efﬁcient metastasis formation is dependent on tumor
cell autonomous biological programs that deﬁne migration,
intravasation survival and extravasation [14]. For xeno-
transplantation models, immune cell responses to foreign
antigens on the injected tumor cells need to be avoided,
necessitating the use immunocompromised hosts.
The most widely used immunodeﬁcient mice (nude and
SCID) lack the adaptive immune response. However, these
mice still harbor large numbers of cells of the innate
immune system, including natural killer (NK) cells [17].
These cells are important in the killing of viable circulating
tumor cells that, through enhanced invasion and intrava-
sation programs, have efﬁciently escape the primary tumor
and have the potential to form metastasis [18–25]. Indeed,
we showed previously that the MTLn3 cells are killed by
the circulating NK-cells in Fischer 344 rats, thus prevent-
ing efﬁcient lung metastasis formation. Although pre-
treatment with NK-depleting antibodies allowed
experimental lung metastasis formation in this model [26,
27], continuous NK depleting antibody injection is an
undesirable requirement for a breast/tumor metastasis
model. To study breast tumor progression and metastasis
formation using MTLn3 cells expressing the EGF receptor,
an appropriate animal model with a compromised innate
and adaptive immune system was still required.
The goal of the current study was to develop an MTLn3
cell breast tumor metastasis animal model that allows the
unbiased analysis of tumor cell-dependent metastasis pro-
grams, independent of adaptive and innate immune system
surveillance. We ﬁrst show that increased expression of the
ErbB1 receptor in MTLn3 cells was required for lung
metastasis formation in Rag2
-/- cc
-/- mice. Secondly, by
comparing different immune deﬁcient mouse models, we
conﬁrm that Rag2
-/- cc
-/- mice, which lack NK cells, are
an ideal recipient animal model for MTLn3 and 4T1 cells
to study the metastasis process. In conclusion, we have
established an improved animal model that can be used to
study the biological steps that are essential in the formation
of distant metastasis.
Materials and methods
Cell lines
MTLn3 rat mammary adenocarcinoma cells [28] were
cultured as previously described [29]. MTLn3-GFP-ErbB1
and MTLn3-GFP cell-lines were previously described [16]
and were maintained in aMEM (Life Technologies, Inc.,
Gaithersburg, MD) supplemented with 5% fetal bovine
serum (Life Technologies). The mouse mammary meta-
static 4T1-luc cell-line was purchased from Caliper Life-
science and cultured in RPMI-1640 supplemented with
10% fetal bovine serum (Life Technologies).
Reagents
Mouse anti-human ErbB1 was purchased from Calbiochem
(EMD Biosciences, San Diego, California). Rabbit anti-
human ErbB1 used for immunoblotting was purchased
from Cell Signaling Technology (Danvers, MA). Goat anti-
mouse APC was purchased from Cedarlane (Ontario,
Canada). Alpha modiﬁed minimal essential medium (a-
MEM), Fetal Bovine Serum (FBS), phosphate buffered
saline (PBS) and trypsin were from Life Technologies
(Rockville, MD, USA).
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Flow cytometry
MTLn3 were harvested and incubated for 45 min with
50 ll of mAb ErbB1 (2 lg/ml in PBS). Cells were washed
with cold PBS and incubated for 45 min with the second-
ary antibody goat-anti mouse APC in PBS (2 lg/ml).
Finally, cells were washed and suspended in 0.3 ml PBS.
ErbB1 and GFP expression were analysed by ﬂow
cytometry (FACScalibur, Becton Dickinson).
Immunoblotting
Cells were scraped in ice-cold TSE (10 nM Tris–HCl,
250 mM sucrose, 1 mM EGTA, pH 7.4) supplemented
with inhibitors. After sonication of either cells or tissue,
protein concentrations were determined by the Bio-Rad
(Hercules, CA) protein assay using IgG as a standard.
Equal amounts of total cellular protein were separated by
7.5% SDS–PAGE and transferred to polyvinylidene
diﬂuoride membranes (Millipore, Billerica, MA). Blots
were blocked with 5% (w/v) bovine serum albumin in
TBST [0.5 mol/l NaCl, 20 mmol/l Tris–HCl, 0.05% (v/v)
Tween 20 (pH 7.4)] and probed with primary antibody
(overnight, 4C) followed by incubation with secondary
horseradish peroxidase–coupled antibody and visualized
with Enhanced Chemiluminescence Plus reagent (Amer-
sham Biosciences, Uppsala, Sweden) by scanning on a
multilabel Typhoon imager 9400 (Amersham Biosciences).
Animals
Female BALB/c nu/nu, SCID [CB17/lcr-Prkdc
scid/Crl] and
SCID Beige [CB17/lcr.Cg-Prkdc
scid Lyst
bg/Crl] mice aged
between 6 and 7 weeks were purchased from Charles River
(L’Arbresle, France). BALB/c mice aged between 6 and
7 weeks were purchased from Janvier (Uden, The Neth-
erlands). 6-week old Rag2
-/- cc
-/- mice were obtained
from in house breeding. Animals were housed in individ-
ually ventilated cages under sterile conditions containing
three mice per cage. Sterilised food and water were pro-
vided ad libitum.
Spontaneous and experimental metastasis assays
To measure spontaneous metastasis, tumor cells were
grown to 70–85% conﬂuence before being harvested for
cell counting. Cells (5 9 10
5 for the MTLn3 or 1 9 10
5 for
the 4T1-luc) were injected into the right thoracic mammary
fat pads of the different mouse strains. Cells were injected
in a volume of 100 ll of PBS without Ca
2? and Mg
2?
through a 25-gauge needle. Tumor growth rate was
monitored at weekly intervals after inoculation of tumor
cells. Horizontal (h) and vertical (v) diameters were
determined, and tumor volume (V) was calculated (V = 4/
3p(1/2[H(h 9 v)]
3). After 3 or 4 weeks, the animals were
anesthetized with pentobarbital and the lungs were excised
and rinsed in ice-cold PBS. For the GFP-labeled MTLn3
cell-lines, the right lung was used to count the tumor
burden. For rough estimation, the right lungs were imaged
with the Fluorescent imaging unit IVIS (see below). And
for detailed quantiﬁcation, the ﬂat side of the right lung
was analysed with the immunoﬂuorescence microscope.
With a 910 objective lens, we screened the ﬂat surface of
the lobe and counted the number of GFP positive metas-
tases. Subsequently, the right lung was ﬁxed in 4% para-
formaldehyde. The left lung was injected with ink solution,
de-stained in water and ﬁxed in Fekete’s (4.3% (v/v) acetic
acid, 0.35% (v/v) formaldehyde in 70% ethanol). For the
4T1-luc cell-line, the lung tumor burden was quantiﬁed by
counting the number of surface metastases which were
represented by white spots on the ink-injected left lung.
For the experimental lung metastasis assay, 2 9 10
5
MTLn3 cells were injected into the lateral tail veins of 5- to
7-week-old female Rag2
-/- cc
-/- mice. Three to four
weeks after injection, the mice were euthanized, and the
lungs were removed and subjected to ﬂuorescent imaging
and histologic examination as described below.
Fluorescent imaging
Fluorescent imaging (FLI) was performed with a high
sensitivity, cooled CCD camera mounted in a light-tight
specimen box (IVIS
TM; Xenogen). Imaging and quantiﬁ-
cation of signals were controlled by the acquisition and
analysis software Living Image
 (Xenogen). For ex vivo
imaging, lungs were excised, placed into a petri dish, and
imaged for 1–2 min. Tissues were subsequently ﬁxed as
above and prepared for standard histopathology evaluation.
Measurement of tumor cell blood burden
At the end point of the MTLn3 spontaneous metastasis
assay, mice were sacriﬁced with Nembutal. The right side
of the thoracic cavity was exposed by a simple skin ﬂap
surgery. Blood was taken from the right atrium via heart
puncture with a 25-gauge needle and 1-ml syringe coated
with heparin. Blood (0.2–1.0 ml) was harvested from each
animal. The blood was immediately plated into 100-mm-
diameter dishes ﬁlled with 5% fetal bovine serum/aMEM
growth medium. The next day, the plates were rinsed with
fresh medium containing 0.8 mg/ml geneticin to selec-
tively grow the tumor cells. After 3–7 days, all dishes were
scanned for GFP expression with a Typhoon imager 9400
(Amersham Biosciences). The tumor cell clones were
Clin Exp Metastasis (2009) 26:673–684 675
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blood burden was calculated as total colonies in the dish
divided by the volume of blood taken.
Tumor histology and quantitative assessment
of the efﬁciency of metastasis
The primary tumors and lungs from each mouse were used
for histological analysis. Samples were ﬁxed in formalin
and embedded in parafﬁn, and 5-lm sections were stained
with H&E.
Statistical analysis
Student’s t test was used to determine if there was a sig-
niﬁcant difference between two means (P\0.05). Values
are presented as mean ± SD. Signiﬁcant differences are
marked in the graphs.
Results
ErbB1 overexpression in MTLn3 cells delays tumor
growth but facilitates breast cancer lung metastasis
formation in Rag2
-/- cc
-/- mice
Since the EGF receptor is often over expressed in breast
cancer progression [12, 13], we used MTLn3-GFP-ErbB1
cells, because of the high likelihood of success for
metastasis formation. First, we veriﬁed whether ErbB1
overexpression is indeed essential for metastases formation
in the Rag mouse model. Therefore we compared MTLn3-
GFP with MTLn3-GFP-ErbB1 cells. Increased expression
of ErbB1 protein in the MTLn3-GFP-ErbB1 cell-line was
conﬁrmed by Western blot analysis (Fig. 1a) and ﬂow
cytometry (Fig 1b). We also conﬁrmed that GFP was
equally expressed in both cell-lines (Fig. 1b). The expres-
sion of GFP was used to count the lung metastases and
Fig. 1 ErbB1 over-expression
affects tumor growth rate of
MTLn3 in a spontaneous
metastasis assay. a Western blot
of ErbB1 expression in MTln3-
GFP and MTLn3-GFP-ErbB1
cell-lines. b Fluorescence-
activated cell sorting (FACS)
analysis of cell surface
expression levels of human
ErbB1 and GFP expression
levels for MTLn3-GFP and
MTLn3-GFP-ErbB1 cell-lines.
c Primary tumor growth
measured by caliper during
spontaneous metastasis assay.
Rag mice were inoculated with
MTLn3-GFP (n = 13) and
MTLn3-GFP-ErbB1 (n = 17)
cells (MTln3-GFP-ErbB1 vs.
MTLn3-GFP, P\0.0001). d
Primary tumor weight at the end
point of the spontaneous
metastasis assay (P[0.05)
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123detect the tumor cells in blood. To determine the effects of
increased ErbB1 expression on tumor growth and metas-
tasis, MTLn3-GFP-ErbB1 and the control cell-line
MTLn3-GFP were injected into the mammary fat pads of
Rag2
-/- cc
-/- mice, and tumor growth was monitored. All
animals implanted with tumor cells developed tumors at
the site of injection. The tumor growth of MTLn3-GFP
cells was faster than that of MTln3-GFP-ErbB1 cells
(Fig. 1c). Animals were sacriﬁced when the primary tumor
reached similar volume for the two cell-lines between day
25 and 30. Indeed, there was no signiﬁcant difference in
tumor weight at the time of sacriﬁce (Fig. 1d). The animals
were checked for spontaneous metastasis efﬁciency. Mice
implanted with MTLn3-GFP-ErbB1 cells had signiﬁcantly
more lung metastases than mice implanted with MTLn3-
GFP cells (Fig. 2a) also evidence by ﬂuorescence imaging
(Fig. 2b). Histological analysis of the lungs showed an
absence of micro-metastases in the MTLn3-GFP group
(Fig. 2c). In the lungs of mice implanted with MTLn3-
GFP-ErbB1 cells, many macro-metastases could be
detected on the surface and also throughout the lungs
(Fig. 2c). No correlation was founded between tumor
weight and number of lung metastases (Fig. 2d). We con-
sidered whether the additional period allowed for mice
with delayed tumor growth could account for the increased
number of lung metastases in the MTLn3-GFP-ErbB1
group. Therefore, we performed an experiment where both
groups were sacriﬁced after 25 days. The primary tumors
of the MTLn3-GFP-ErbB1 group again showed reduced
growth rate (supplementary data Fig. 2a) and tumor weight
was much lower than the MTLn3-GFP tumors (supple-
mentary data Fig. 2b). Despite this reduced tumor growth,
there was a trend toward a greater number of lung metas-
tases in ErbB1-expressing tumor bearing mice (supple-
mentary data Fig. 2c). We conclude from these results that
increased expression of ErbB1 in MTLn3 cells results in
reduced tumor growth but increased number of lung
metastasis in Rag mice.
ErbB1-driven metastasis in the Rag2
-/- cc
-/- mice is
dependent on enhanced intravasation in the primary
tumor
Intravasation is a crucial step in the process of metastasis
formation and ErbB1 signaling is thought to be a key factor
in this process. Intravasation can be evaluated by deter-
mining the number of tumor cells present in blood col-
lected from the right atrium of the heart. Animals bearing
MTLn3-GFP tumors had very few tumor cells/ml of blood,
whereas animals bearing MTLn3-GFP-ErbB1 tumors had
an average of 170 tumor cells/ml of blood (Fig. 3a, b). In
conclusion, increased ErbB1 expression in MTLn3 cells
Fig. 2 ErbB1 over-expression
signiﬁcantly enhances lung
metastasis formation
independent of tumor weight. a
Lung metastases counted with a
ﬂuorescent microscope at 910
magniﬁcation (only one side of
the left lung) at the end point of
the spontaneous metastasis
assay (MTln3-GFP-ErbB1
versus MTLn3-GFP,
P\0.0001). b Lung metastases
visualized with the FLI (GFP
detection) after spontaneous
metastasis assay with the
MTLn3-GFP and the MTLn3-
GFP-ErbB1 cells. c H&E
staining of lung tissue of
MTLn3-GFP (left panel) and
MTLn3-GFP-ErbB1 cells (right
panel) injected mice. d Lung
metastases plotted against tumor
weight of MTLn3-GFP-ErbB1
tumors bearing mice (n = 17)
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123enhances intravasation and thereby metastasis formation in
the Rag2
-/- cc
-/- mice.
Finally, we determined whether ErbB1-mediated
enhanced lung metastasis was also related to increased
homing, extravasation, or growth of the tumor cells in
the lungs. For this purpose we compared the MTLn3-
GFP and MTLn3-GFP-ErbB1 cell lung metastasis fol-
lowing injected into the lateral tail vein (200,000 cells)
of 5- to 7-week-old female Rag mice. Four weeks after
injection, mice were sacriﬁced, and the lungs were
removed and examined for metastases. While in the
spontaneous metastasis assay signiﬁcantly more metasta-
ses were observed in the MTLn3-GFP-ErbB1 trans-
planted group (Figs. 1, 2), animals receiving MTLn3-
GFP or MTLn3-GFP-ErbB1 cells in the tail vein devel-
oped a comparable number of metastatic lesions in the
lungs (Fig. 3c, d). These results indicate that the
enhanced ErbB1-dependent metastasis formation from the
primary tumor is principally determined by intravasation
and/or enhanced invasion rather than homing events at
the target organ.
NK cells do not interfere with primary tumor growth
Previously, we demonstrated a negative role of NK
immune cells in lung metastasis formation in Fischer 344
rats [27]. We analyzed several immune deﬁcient mouse
models for their capacity to support orthotopic breast
cancer metastasis formation. Since ErbB1 enhances in-
travasation of MTLn3 tumor cells and GFP enables FLI
and easy counting of individual lung metastases [14, 30,
31], we used the MTLn3-GFP-ErbB1 cell line to screen for
the most suitable orthotopic breast/tumor metastasis model.
We selected four mouse strains with different immunode-
ﬁciency backgrounds (see Table 1). The conventional nude
mice still possess B lymphocytes and NK cells. Severe
combined immunodeﬁciency (SCID) mice lack T and B
cells but have NK cells. SCID Beige mice also lack NK
cells [6, 18, 20–23, 25, 32]. Rag2
-/- cc
-/- mice lack both
the adaptive and innate immune response. The common
gamma (cc) knock-out mouse lacks functional receptors for
many cytokines including IL-2, IL-4, IL-7, IL-9 and IL-15.
As a consequence, lymphocyte development is greatly
Fig. 3 ErbB1-driven metastasis is due to enhanced intravasation
ability and not due to enhanced growth of metastases in the lungs. a
Scan with Typhoon imager of two dishes where approximately 0.7 ml
of blood directly drawn from the right ventricle was cultured for
7 days. GFP colonies of blood collected from MTLn3-GFP inoculated
mouse (left side) and from MTLn3-GFP-ErbB1 inoculated mouse
(right side). b Tumor blood burden at the end point of the spontaneous
metastasis assay. Colonies were counted after 7 days of culture
(MTLn3-GFP versus MTLn3-GFP-ErbB1, P\0.05). c Lung metas-
tases counted with a ﬂuorescent microscope at 910 magniﬁcation
(only one side of the left lung) at the end point (day 28) of the
experimental metastasis assays (tail vein MTLn3-GFP versus tail vein
MTLn3-GFP-ErbB1, P[0.05). d Lung metastases visualized with
FLI after experimental metastasis assay with MTLn3-GFP and
MTLn3-GFP-ErbB1 cells only
678 Clin Exp Metastasis (2009) 26:673–684
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the residual T and B cells in the cc
-/- background is
obtained by crossing these mice to the recombinase acti-
vating gene 2 (Rag2) deﬁcient mice [6, 32]. All the mice
were injected with 500,000 MTLn3-GFP-ErbB1 cells in
the right thoracic mammary fat pad. We followed the pri-
mary tumor growth for 4 weeks and sacriﬁced the mice
when the tumors reached an average size of
10 mm 9 10 mm. The primary tumor growth rate in all
mice strains except for the SCID Beige mouse was similar.
The xenografts in the SCID Beige appeared to show
delayed growth but the difference with the other mouse
strains was not signiﬁcant. Furthermore, the average tumor
weight was comparable with the other three mouse strains
(Fig. 4a, b). Overall the primary tumor volume varied
between 300 and 500 mm
3 (Fig. 4a) and tumor weight
between 300 and 500 mg (Fig. 4b). Both volume and
weight were not signiﬁcantly different between the four
mouse strains. No difference was noticed in tumor orga-
nization, as determined by H&E staining (data not shown).
No necrotic regions were observed in any of the tumors of
the different mice strains. Since there was no signiﬁcant
difference in tumor weight especially between the SCID
and the SCID Beige, the results suggest that NK cells do
not interfere with the tumor growth of the MTLn3-GFP-
ErbB1 cells.
Efﬁcient orthotopic lung metastasis formation
in the Rag2
-/- cc
-/- and SCID Beige mice
After orthotopic transplantation of MTLn3 cells into the
mammary gland of the four different mouse strains, pri-
mary tumors formed in all mice. Next we checked for the
number of lung metastases after sacriﬁcing the mice. The
presence of GFP in the MTLn3 cells allowed the quanti-
ﬁcation of the lung metastases and classiﬁcation according
to their size by ﬂuorescence microscopy (Fig. 5b). While
there was no signiﬁcant difference in primary tumor
growth in the four different mouse strains (Fig. 4), almost
no lung metastases were observed in nude or SCID mice
(Fig. 5a). Many lung metastases were observed in both
Rag2
-/- cc
-/- and SCID Beige mice, although the latter
showed signiﬁcantly fewer metastases than the Rag2
-/-
cc
-/- mice (Fig. 5a). Visualization of individual metasta-
ses by immunoﬂuorescence microscopy demonstrated that
in the SCID Beige mice the size of the metastases ranged
from less than 0.1 to 0.3 mm
2 while in the Rag2
-/- cc
-/-
mice they were all above 0.3 mm
2 (Fig. 5b). When the
lungs were injected with ink, it was not possible to observe
metastases in the SCID Beige; they were only visible with
HE staining. However metastases were clearly visible in
the Rag2
-/- cc
-/- mice (Fig. 5c). Since NK cells are still
present in both nude and SCID mice but are absent in both
Table 1 Characteristics of immunodeﬁcient mice used
Strain Adaptive immunity Innate immunity Reference
BALB/c nu/nu 6 [Nude] T cell deﬁciency [52]
CB17/lcr-Prkdc
SCID/Crl [SCID] T and B cell deﬁciency [53–55]
CB17/lcr.Cg-Prkdc
SCID Lyst
bg/Crl [SCID Beige] T and B cell deﬁciency Reduced NK cell function [35, 36, 56]
Rag2
-/- cc
-/- [Rag] T and B cell deﬁciency NK cell deﬁciency [6, 32, 57, 58]
Fig. 4 MTLn3-GFP-ErbB1
cells have a similar growth rate
in Nude, SCID, SCID Beige and
Rag2
-/- cc
-/- mice. a Tumor
growth rate monitored in the
Nude (n = 5), SCID (n = 5),
SCID Beige (n = 5) and
Rag2
-/- cc
-/- (n = 6) mice by
measuring the volume over the
time period of the experiment. b
Primary tumor weight at the end
point of the spontaneous
metastasis assay (P[0.05)
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123SCID Beige and Rag2
-/- cc
-/- mice, it shows that the
presence of NK cells is the limiting factor for efﬁcient lung
metastasisformationinorthotopicbreastcancermodels.The
beige mutation not only results in loss of cytotoxic T cells
and selective impairment of NK cell functions but also in
macrophage defects. Macrophages have been shown to
inﬂuence MTLn3 lung metastasis formation [33, 34]. This
could explain the lower average tumor weight and most
probablythereducednumberoflungmetastasesintheSCID
BeigemicecomparedwiththeRag2
-/-cc
-/-mice[35,36].
Efﬁcient orthotopic lung metastasis formation
in the Rag2
-/- cc
-/- using the 4T1-luc cell-line
Orthotopic transplantation of MTLn3-GFP-ErbB1 cells into
themammaryglandofRag2
-/-cc
-/-miceresultedinahigh
number of lung metastases. We also examined whether the
Rag2
-/- cc
-/- mouse is a good recipient for another highly
metastatic cell-line, 4T1-luc. This cell-line is supposed to
metastasize easily to the lungs and other target organs in the
syngeneic orthotopic mouse model the Balb/c mouse [37].
We injected 100,000 4T1-luc cells in the T4 mammary fat
pad of both Rag2
-/- cc
-/- and Balb/c mice. Over a time
period of 3 weeks, we observed a signiﬁcantly higher tumor
growth rate in the Rag2
-/- cc
-/- mice (Fig. 6a), which we
attribute tothe inﬂuence of the immune system ofthe Balb/c
mouse. At time of sacriﬁce, the primary tumor weight was
similar in both mouse strains (Fig. 6b), however there were
signiﬁcantlymoreandlargerlungmetastasesintheRag2
-/-
cc
-/- mice than in the Balb/c mice (Fig. 6c, d). After
3 weeks, only a high number of lung metastases formed by
4T1-luccellscouldbeobservedintheRag2
-/-cc
-/-mouse
model. We therefore conclude that Rag2
-/- cc
-/- mice
represent a suitable breast cancer mouse model.
Discussion
Modeling metastasis in vivo is challenging but necessary
for studying the mechanisms underlying the tumor cell
Fig. 5 NK cells interfere with
lung metastasis formation. After
sacriﬁce, the number of GFP-
positive lung metastases was
counted ex vivo using an
inverted ﬂuorescent microscope
and a 910 objective lens. a
Number of lung metastases at
the end point of the spontaneous
metastasis assay (t-test,
P\0.05). b Images of the four
different sizes of lung
metastases encountered during
counting. Bar represents
100 lm. c After 5 weeks, lungs
were isolated, injected with ink
(right lobes) and lung (left lobe)
sections were stained with H&E
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123biological processes (e.g. cell migration) that enable certain
cells to spread to other parts of the body [7]. EGFR-sig-
naling is a pathway that is known to be involved in breast
tumor progression. We examined whether EGFR overex-
pression in MTLn3 cells results in increased number of
lung metastases in the Rag2
-/- cc
-/- mice. In contrast of
previous ﬁndings [12, 13, 16], our data indicate that
increased expression of ErbB1 in the MTLn3 mammary
adenocarcinoma cells results in slower primary tumor
growth. In vitro, MTLn3-GFP-ErbB1 cells show an
increased proliferation rate compared with control cells,
suggesting instead that there may be a difference in cell
survival. Indeed, MTLn3-GFP-ErbB1 cells are less able to
tolerate culture at high density compared to MTLn3-GFP
control cells. MTLn3-GFP-ErbB1 cells may be less toler-
ant of the fat pad injection procedure resulting in fewer
surviving cells that can develop into a primary tumor.
ErbB1 overexpression enhances the ability to intravasate
and, thus, provide sufﬁcient seeding capacity to allow lung
metastasis formation in the Rag2
-/- cc
-/- mice. Indeed,
there were an increased number of tumor cells in the cir-
culation of mice with ErbB1-expressing tumors, while few
cells could be detected in the blood collected from control
tumor bearing mice. Furthermore, the efﬁciency of lung
colonization by MTLn3 cells (experimental metastasis
assay) was independent of ErbB1 overexpression. These
results are consistent with previous in vivo studies showing
that ErbB1 expression can enhance invasiveness—most
probably through increased chemotaxis to gradients of EGF
[33, 34]. The angiogenesis marker, CD31, failed to reveal
differences in blood vessel density through the primary
tumor of both groups (data not shown). The presence of
macrophages in the Rag2
-/- cc
-/- mice allows the para-
crine loop with tumor cells to take place and thus enhances
invasiveness in response to EGF.
In this study, we have shown that the presence of
remaining innate immune cells, including NK cells, in the
nude and SCID mouse does not affect the growth of the
primary tumor but inhibits the formation of lung metastases
[6, 17, 27, 38]. Indeed, we have found that the Rag2
-/-
cc
-/- mouse which lacks NK cells is an excellent recipient
animal model to study breast tumor formation and pro-
gression when using MTLn3 overexpressing ErbB1 cells or
4T1 cells. Previous reports demonstrated the contribution
of NK cells in tumor growth and metastasis [27, 39–42]. In
particular, Dewan et al. [43] demonstrated the direct role of
NK cells in tumor growth and metastasis using NOD/
SCID/cc
null (NOG) mice lacking T, B and NK cells which
are similar to the Rag2
-/- cc
-/- mice used in our study.
They showed both increased efﬁciency of engraftment
(subcutaneous inoculation only) and spontaneous metasta-
sis of the human breast cancer cell-line MB-MDA-231 in
the NOG mice compared to the SCID mice demonstrating
the critical role of NK cells in tumor growth and metastasis
[44]. In our study, we used the rat mammary adenocarci-
noma MTLn3 cell-line overexpressing ErbB1. Although
we did not observe a signiﬁcant role for NK cells in
engraftment and primary tumor growth, they did appear to
be important for the formation of spontaneous lung
metastases. Since the Rag2
-/- cc
-/- and NOG mice have
Fig. 6 4T1-luc cells
metastasize more efﬁciently in
the Rag2
-/- cc
-/- mice than in
their syngeneic mouse model
the Balb/c. a Tumor growth rate
of the 4T1 cells monitored in
the Rag2
-/- cc
-/- mice (n = 5)
and in the Balb/C mice (n = 5)
over 3 weeks. b Primary tumor
weight at the end point of the
spontaneous metastasis assay
(P[0.05). c Example of lung
injected with ink (right lobe)t o
show number and size of
metastases in both mouse
models. d Lung metastases at
the end point of the spontaneous
metastasis assay (t-test,
P = 0.0040)
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123similar immunodeﬁciencies, i.e. T, B, and NK cell reduc-
tions, similar results for the NOG and Rag2
-/- cc
-/-
mouse were to be expected. Zhang et al. [45] also conclude
that Rag2
-/- cc
-/- mice, similar to NOD/SCID/cc
null
(NOG) mice, provide a suitable immunodeﬁcient setting
for human engraftment. Nevertheless, our results con-
cerning efﬁcient engraftment of the tumor cells do not
show that NK cells play a role in this tumor progression
step. Tumor growth in the SCID Beige mice was slightly
delayed although these also lack NK cells. In fact, the beige
mutation not only results in loss of cytotoxic T cells and
selective impairment of NK cell functions but also in
macrophage defects which could explain the lower average
tumor weight and most probably the reduced number of
lung metastases [35, 36]. Indeed, it has been shown that
macrophages can form a paracrine loop with tumor cells to
enhance invasiveness in response to EGF stimulation [33,
34, 46, 47]. Reduced macrophage activity in SCID Beige
mice could therefore explain why tumor growth and the
number of lung metastases were reduced compared to Rag
mice.
To further conﬁrm that the Rag mouse is a suitable
animal model for studying breast cancer progression, we
injected two human xenografts models MDA-MB-231-luc
[48] and a bone metastastic variant BO2-MDA-MB-231-
luc [49] cell-lines. These MDA-MB-231 cell lines poorly
grew after orthotopic transplantation in Rag mice (data not
shown). Typically, these cell lines are used in intracardial
injection studies for bone metastasis model. The parental
MB-MDA-231 cells do grow orthopically to 1 cm in
diameter typically in 30–35 days after inoculation of
1 9 10
6 cells in SCID mice. After removal of the mam-
mary fat pad tumors, mice are then sacriﬁced 4–5 weeks
later and few spontaneous metastases can be detected [50].
Although not tested, we anticipate that the parental MB-
MDA-231 cells would form orthotopic breast tumors in
Rag2
-/- cc
-/- mice, but the necessary removal of the
primary tumor for further metastases development as well
as the ultimate number of lung metastasis formed, does not
ﬁt our requirements for an easy and reliable breast cancer/
metastasis animal model. In addition to our MTLn3 cell
line, we also tested the 4T1 mouse mammary tumor cell-
line, which is known to be one of the only few breast
cancer models with the capacity to metastasize efﬁciently
to sites affected in human breast cancer [51]. When
introduced orthotopically in the syngeneic Balb/c mouse
model which possesses an intact immune system, 4T1
should be capable of metastasising to several organs typi-
cally affected in breast cancer [12, 13]. However, when we
injected the 4T1-luc cells in the Rag2
-/- cc
-/- and Balb/c
mice, we could only detect lung metastases in the Rag2
-/-
cc
-/- mice although a primary tumor formed in both
mouse strains. Even after 3 weeks of experiment the
primary tumor started to shrink in the Balb/c mice which
has been described as a biphasic growth related to immune
system function [37]. Indeed, Tao et al. observed a
regression in weeks 2 through 4 in normal BALB/c mice
which was associated with necrosis and inﬁltration of
leukocytes. Biphasic tumor growth did not occur in athy-
mic nude or SCID BALB/c mice suggesting involvement
of an acquired immune response in the effect. We also
injected the 4T1-luc in Balb/c mice purchased from dif-
ferent suppliers (data not shown). The results were similar:
very few lung metastases detectable. In conclusion, our
results suggest that NK cells play an important role in
inhibiting metastasis formation but not in tumor growth.
In summary, ErbB1 overexpression in the MTln3 cells
delayed the primary tumor growth but was essential for
efﬁcient intravasation and lung metastasis formation. This
suggests a role for ErbB1 expression in tumor cells to drive
the biological processes that are essential in intravasation,
such as cell motility. Secondly, we provide evidence for the
crucial role of NK cells in metastasis formation but not in
tumor growth. Metastasis formation is a key determinant of
poor prognosis for breast cancer patients; enhancing NK
activity is therefore a potential immunotherapeutic strategy
for combatting this detrimental step.
The Rag2
-/- cc
-/- mouse model, in combination with
MTLn3-ErbB1 and 4T1 tumor cells, is a clinically relevant
model for the study of breast cancer cell growth and
metastasis. The 4T1 syngeneic metastatic breast cancer
model may be useful to validate potential gene targets and
processes implicated in cell migration and intravasation.
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